Form 4: Immunocore Holdings Director Herbst Granted Share Options

Director Roy Steven Herbst receives share options in Immunocore Holdings plc.

Summary

• Roy Steven Herbst, a director of Immunocore Holdings plc, was granted share options on May 15, 2025.
• The options give him the right to buy 26,198 ordinary shares at an exercise price of $29.06 per share.
• The options vest on the earlier of May 15, 2026, or the day before the next annual general meeting, contingent on continuous service.
• The options expire on May 14, 2035.

Sentiment

Score: 7

Explanation: The document indicates a standard equity grant to a director, which is generally viewed neutrally to positively as it aligns interests. There are no red flags or negative implications.

Positives

• The granting of share options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard practice for publicly traded companies to incentivize and retain key personnel, such as directors, through equity-based compensation.

Comparison to Industry Standards

• Granting share options to directors is a common practice in the biotechnology industry to align their interests with shareholders.
• The vesting schedule and exercise price are typical for such grants, often tied to continued service and market value at the time of the grant.
• Comparable companies like Adaptimmune Therapeutics and CRISPR Therapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The granting of share options could have a slightly dilutive effect on existing shareholders.

Key Dates

Keywords

Immunocore Holdings, Share Options, Director, Form 4, Beneficial Ownership, Equity Securities